Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Contributed by: Business Wire

Logo

Tags

Research

Genetics

Clinical Trials

Biotechnology

General Health

Pharmaceutical

Health

Science

Oncology

Other Science

Evaluation and Potential Licensing Agreement With BioCopy

More Like This

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates